Lilly Initiates Phase 3 Trial of LY-CoV555 for Prevention of COVID-19 at Long-Term Care Facilities in Partnership with the National Institute of Allergy and Infectious Diseases (NIAID)
LY-CoV555 is a neutralizing IgG1 monoclonal antibody (mAb) directed against the spike protein of SARS-CoV-2. It is designed to block viral attachment and entry into human cells, potentially preventing and treating COVID-19.
Vivage is excited to be a part of this first-of-its-kind study involving up to 2,400 residents and staff at long-term care facilities in the U.S.
Learn MoreTools & Resources

Colorado Residents

Long-Term Healthcare Providers
